by telrheum | May 25, 2024 | Biologic Therapy, Colitis, IL-23 Inhibitors, Interleukin Inhibitors, tumour necrosis factor inhibitors (TNFis)
Background Ulcerative colitis is a chronic inflammatory condition affecting the colon. A recent study investigated the effectiveness of combining two drugs, Simponi, which blocks tumor necrosis factor-alpha, and Tremfya, which inhibits interleukin-23. This combination...
by telrheum | Mar 11, 2024 | JAK Inhibitor, Biologic Therapy, Colitis, Rheumatoid Arthritis, Spondyloarthritis
Rinvoq, a newer medication in the field of rheumatology and immunology, has shown remarkable efficacy in managing several chronic inflammatory conditions. As a selective Janus kinase (JAK) inhibitor, Rinvoq specifically targets pathways that contribute to the...
by telrheum | Mar 11, 2024 | Rheumatoid Arthritis, Colitis, JAK Inhibitor
Xeljanz, known generically as tofacitinib, is a medication that represents a significant advancement in the treatment of various autoimmune diseases. Approved by the FDA, Xeljanz operates by inhibiting Janus kinase (JAK) pathways, which are crucial in the process of...